Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | DRD1 | P21728 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | PDE7A | Q13946 | 2/20 | 0.35 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21580724 | 1.00 | POLB (0.46) | POLBNPC1RAB9AARKMT2A | |
| SCHEMBL31089890 | 0.99 | POLB (0.44) | POLBNPC1RAB9AARKMT2A | |
| SCHEMBL21580710 | 0.99 | POLB (0.44) | POLBNPC1RAB9AARKMT2A | |
| SCHEMBL21580661 | 0.97 | POLB (0.42) | POLBNPC1RAB9AARKMT2A | |
| SCHEMBL21580721 | 0.92 | POLB (0.45) | POLBNPC1RAB9AARKMT2A | |
| SCHEMBL31089899 | 0.92 | POLB (0.45) | POLBNPC1RAB9AARKMT2A | |
| SCHEMBL21580774 | 0.91 | POLB (0.37) | POLBNPC1RAB9AARALDH1A1 | |
| SCHEMBL21580767 | 0.91 | POLB (0.37) | POLBNPC1RAB9AARKMT2A | |
| SCHEMBL21580714 | 0.91 | POLB (0.37) | POLBNPC1RAB9AARALDH1A1 | |
| SCHEMBL31089811 | 0.91 | POLB (0.37) | POLBNPC1RAB9AARALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12090146-B2 | Substituted-pyridinyl compounds and uses thereof | BIONOMICS LIMITED (AU) | 2024-09-17 | — | — | US | disclosed |
| EP-3853216-B1 | 3-[2-(PHENOXY)-4-PYRIDYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES FOR THE TREATMENT OF COGNITIVE DYSFUNCTION AND CNS DISORDERS | BIONOMICS LTD (AU) | 2024-09-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12090146-B2 | Substituted-pyridinyl compounds and uses thereof | GABRE, GAP43, GRIN2A | POLB 2270/4885NPC1 4607/4885RAB9A 2860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.